Regulatory Biogen’s salanersen gains FDA breakthrough therapy designation for SMA Pharmaceutical Business ReviewThis advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA.NeuroscienceRead full story pharminent June 5, 2026 (Last updated: June 5, 2026) Pharmaceutical Business Review This advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer signs licence agreement with Chai for AI drug discoveryNext: Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
